Who are Mycophenolate Mofeti's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CsA+MMF+CS, sirolimus (drug), mmf (drug), Tacrolimus/MMF, Tacrolimus and Mycophenolate-mofetil, LCP-tacrolimus QD + MMF BID, Myfortic Escalation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mycophenolate-mofeti.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Mycophenolate Mofeti — Competitive Intelligence Brief

Mycophenolate Mofeti (Mycophenolate Mofeti) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inosine monophosphate dehydrogenase (IMPDH) inhibitor. Area: Immunology.

marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor IMPDH type II Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Mycophenolate Mofeti (Mycophenolate Mofeti) — National Cancer Institute (NCI). Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing proliferation of T and B lymphocytes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mycophenolate Mofeti TARGET	Mycophenolate Mofeti	National Cancer Institute (NCI)	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II
CsA+MMF+CS	CsA+MMF+CS	Pfizer	marketed	Immunosuppressive combination therapy	Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS)
sirolimus (drug), mmf (drug)	sirolimus (drug), mmf (drug)	University Hospital Muenster	marketed	Immunosuppressive agents (mTOR inhibitor + IMPDH inhibitor combination)	mTOR (sirolimus); IMPDH type II (MMF)
Tacrolimus/MMF	Tacrolimus/MMF	University of Miami	marketed	Immunosuppressant combination	Calcineurin (tacrolimus); IMPDH type II (MMF)
Tacrolimus and Mycophenolate-mofetil	Tacrolimus and Mycophenolate-mofetil	University of Giessen	marketed	Immunosuppressant combination (calcineurin inhibitor + antimetabolite)	Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)
LCP-tacrolimus QD + MMF BID	LCP-tacrolimus QD + MMF BID	University Hospital, Limoges	marketed	Calcineurin inhibitor + antimetabolite combination	Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)
Myfortic Escalation	Myfortic Escalation	East Carolina University	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inosine monophosphate dehydrogenase (IMPDH) inhibitor class)

Hoffmann-La Roche · 2 drugs in this class
East Carolina University · 1 drug in this class
ITB-Med LLC · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
Sanofi · 1 drug in this class
University Hospital, Limoges · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mycophenolate Mofeti — Competitive Intelligence Brief. https://druglandscape.com/ci/mycophenolate-mofeti. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab